COVID toe is the common name for chilblain-like lesions that appear on the toes (and sometimes fingers) during or after a COVID-19 infection. The toes swell and change color, often turning red, purple, or brownish-purple, and the condition primarily affects children, teenagers, and young adults who are otherwise healthy. Most cases resolve on their own within about two weeks, though a small number of people develop persistent symptoms lasting months.
What COVID Toe Looks and Feels Like
The hallmark of COVID toe is swelling and discoloration in one or more toes. On lighter skin, the toes typically start bright red and gradually shift to purple. On darker skin, the discoloration tends to appear purplish from the start, sometimes with round, brownish-purple spots. Some people also develop painful raised bumps, patches of rough skin, or blisters.
The affected toes can feel itchy, painful, or both. The sensations range from mild tingling to enough discomfort that wearing shoes becomes difficult. Fingers can be affected too, though toes are far more common. The lesions sometimes appear on multiple toes at once, and siblings in the same household have been reported developing them around the same time.
Who Gets COVID Toe
COVID toe overwhelmingly affects younger people. In multiple studies across Europe and the United States, the median age of patients with these lesions was around 14 years. An international registry of 505 cases found a mean age of 25. The condition surged specifically in children, teenagers, and young adults during waves of COVID-19, with study groups consistently clustered in the 6-to-29 age range.
Classic chilblains (the non-COVID version) typically show up in young to middle-aged women and are rare in children. The pandemic reversed that pattern, with dermatologists worldwide reporting unusual spikes of chilblain-like lesions in kids and teens who had no prior history of the condition. Traditional risk factors for chilblains include living in cold climates, low body weight, female sex, and smoking, but COVID toe appeared in young, healthy people who didn’t fit the usual profile.
One competing theory suggested the lesions weren’t caused by the virus at all. Some researchers proposed that children stuck indoors during lockdowns simply had more exposure to cold floors from walking barefoot or wearing thin socks. Studies supporting this noted that affected children commonly had cold, sweaty feet, low body weight, and habits like sitting with legs crossed on cool surfaces with the heat turned off. The debate over whether the virus directly causes the lesions or whether behavioral changes during lockdowns played a role has never been fully settled.
Why It Happens
The leading biological explanation centers on the immune system’s antiviral response, specifically a signaling molecule called type I interferon. When your body detects a virus, it releases interferons to coordinate the defense. A strong, early interferon response is associated with clearing the virus quickly and having a mild illness overall.
The catch is that interferons can also affect small blood vessels. When interferon signaling is particularly robust, it can trigger inflammation in the tiny vessels of the fingers and toes, leading to swelling, color changes, and tissue irritation. Under a microscope, skin biopsies from COVID toe show swelling in the upper layers of skin along with clusters of immune cells surrounding small blood vessels and sweat glands. Some samples also show small blood clots forming in the microvasculature.
This mechanism may explain why COVID toe tends to appear in people with mild or even asymptomatic infections. Their immune systems mounted a vigorous early response that cleared the virus effectively but produced collateral inflammation in the extremities. It also helps explain why the condition is rare in older or immunocompromised patients, who are more likely to have a sluggish interferon response and, paradoxically, more severe lung disease.
The Testing Paradox
One of the most confusing aspects of COVID toe is that most people who develop it test negative for the virus. A meta-analysis of case reports and observational studies found that fewer than 15% of patients with COVID toe had a positive PCR test at the time the skin symptoms appeared. In observational studies specifically, the positivity rate was just 7.9%.
This doesn’t rule out a COVID-19 connection. The skin lesions are thought to be a late manifestation of infection, appearing after the virus has already been largely cleared from the body. By the time the toes swell and change color, the window for a positive nasal swab may have already closed. The immune-driven inflammation lags behind the active infection, which is consistent with the interferon theory: the damage to small blood vessels is a downstream consequence of the immune response, not a direct effect of viral replication in the skin.
How Long It Lasts
Most cases resolve spontaneously within about two weeks, particularly in children and teenagers. No treatment is needed for these typical cases, and the skin returns to normal without lasting effects.
A smaller group of patients develops persistent lesions that last well beyond the initial two-week window. Clinicians at post-COVID follow-up clinics have observed patients with chilblain lesions continuing for months, placing COVID toe among the constellation of long COVID symptoms. When lesions persist past 30 days, doctors typically screen for other underlying conditions that may have been triggered by the infection and consider treatments like topical steroids, low-dose aspirin, or medications that improve blood flow to the extremities.
How COVID Toe Differs From Regular Chilblains
COVID toe looks nearly identical to ordinary chilblains, which makes diagnosis tricky. Classic chilblains develop after exposure to cold, damp conditions and are most common in women with cold-sensitive circulation. COVID-associated lesions appeared in warm weather, in populations that don’t typically get chilblains, and often clustered in time with local COVID-19 outbreaks.
The key clinical distinction is between chilblain-like lesions and a more serious pattern called acroischemic lesions, which involve actual tissue damage from severely restricted blood flow. Acroischemic lesions tend to affect older or immunocompromised patients and carry a much higher risk of hospitalization and systemic complications. COVID toe, by contrast, occurs in young, healthy people and signals a robust immune response rather than a failing one.
Managing Symptoms at Home
Because most COVID toe resolves on its own, management is primarily about comfort. Keeping your feet warm, wearing soft socks, and avoiding tight shoes can reduce irritation. If itching or pain is significant, over-the-counter anti-inflammatory creams or cool compresses can help. Avoid rubbing or scratching the affected skin, as broken blisters can become a secondary concern.
If your symptoms are worsening after a couple of weeks rather than improving, or if you develop new lesions, numbness, or significant pain, a dermatologist can evaluate whether topical steroids or other prescription treatments are warranted. Persistent cases sometimes require medications that widen blood vessels and improve circulation to the small vessels in the toes.